deCODE genetics
deCODE GENETICS is a global leader in analyzing and understanding the human genome, with a focus on discovering genetic risk factors for common diseases and developing DNA-based tests and personal genome scans to empower prevention and personalized medicine. Headquartered in Reykjavik, Iceland, deCODE collaborates with research institutions and life sciences companies worldwide, offering genotyping, sequencing, data analysis services, and licensed tests for various diseases.
Industries
Nr. of Employees
large (251-1000)
Patents
Genetic markers for risk management of atrial fibrillation, atrial flutter, and stroke
US-8637244-B2
View DetailsGenetic variants in the TCF7L2 gene as diagnostic markers for risk of type 2 diabetes mellitus
US-7585630-B2
View Details
Genetic markers for risk management of atrial fibrillation, atrial flutter, and stroke
US-8637244-B2
View DetailsGenetic variants in the TCF7L2 gene as diagnostic markers for risk of type 2 diabetes mellitus
US-7585630-B2
View DetailsProducts
DNA-based prostate cancer risk panel
A multi-SNP genetic panel designed to assess individual risk of prostate cancer and inform screening decisions; intended to be used alongside standard clinical measures.
Personal genome analysis service (consumer-facing genome scan)
A personal genome reporting service that provides individuals with information on genetic risk for multiple common diseases and ancestry-related traits.
Genetic marker panel for PSA value correction
A small set of sequence variants used to correct baseline PSA values for genetic influences, enabling a personalized PSA threshold to improve biopsy decision accuracy.
Disease-specific DNA risk panels (cardiovascular, metabolic, ophthalmic, oncologic)
A set of validated multi-marker panels targeting disease areas such as atrial fibrillation/stroke, type 2 diabetes, myocardial infarction, glaucoma and several cancers, intended for clinical risk assessment and research.
DNA-based prostate cancer risk panel
A multi-SNP genetic panel designed to assess individual risk of prostate cancer and inform screening decisions; intended to be used alongside standard clinical measures.
Personal genome analysis service (consumer-facing genome scan)
A personal genome reporting service that provides individuals with information on genetic risk for multiple common diseases and ancestry-related traits.
Genetic marker panel for PSA value correction
A small set of sequence variants used to correct baseline PSA values for genetic influences, enabling a personalized PSA threshold to improve biopsy decision accuracy.
Disease-specific DNA risk panels (cardiovascular, metabolic, ophthalmic, oncologic)
A set of validated multi-marker panels targeting disease areas such as atrial fibrillation/stroke, type 2 diabetes, myocardial infarction, glaucoma and several cancers, intended for clinical risk assessment and research.
Services
High-throughput genotyping and clinical-grade sequencing delivered from an on-site laboratory for research and clinical customers; includes downstream data processing and variant calling.
Laboratory-performed DNA-based risk assessment panels and personalized genetic reports developed and delivered under CLIA and CAP quality systems to support clinical decision-making and screening.
Collaborative research programs with industry and academic partners to identify genetic variants associated with disease, prioritize therapeutic targets and develop companion diagnostics.
High-throughput genotyping and clinical-grade sequencing delivered from an on-site laboratory for research and clinical customers; includes downstream data processing and variant calling.
Laboratory-performed DNA-based risk assessment panels and personalized genetic reports developed and delivered under CLIA and CAP quality systems to support clinical decision-making and screening.
Collaborative research programs with industry and academic partners to identify genetic variants associated with disease, prioritize therapeutic targets and develop companion diagnostics.
Expertise Areas
- Human genetics and gene discovery
- Whole-genome sequencing and variant discovery
- Genome-wide association studies (GWAS) and meta-analysis
- Population-scale imputation and phasing
Key Technologies
- Next-generation sequencing (NGS)
- Whole-genome sequencing
- SNP genotyping arrays
- Imputation and phasing algorithms
News & Updates
deCODE celebrates 25 years of genetic research and discovery.
Dr. Kari Stefánsson received the William Allan Award from the American Society of Human Genetics for substantial contributions to human genetics.
deCODE celebrates 25 years of genetic research and discovery.
Dr. Kari Stefánsson received the William Allan Award from the American Society of Human Genetics for substantial contributions to human genetics.